Investor Information
Event: March 21, 2012 EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.
Recent Releases
May 17, 2012
EDAP to Showcase New Data at 2012 American Urological Association Annual Meeting
May 16, 2012
EDAP Reports First Quarter 2012 Financial Results
Media Coverage
Robotic Ablatherm HIFU's Importance in
Prostate Cancer Surgeries Featured in Major
Conferences
Events & Presentations
May 16, 2012 at 8:30 AM ET
EDAP First Quarter 2012 Results Conference Call
Nov 16, 2011 at 8:30 AM ET
EDAP Third Quarter 2011 Results Conference Call
IR Contact
Stock Information
|
NASDAQ : EDAP Last Price : 1.81 Change : 0.00 0.000% Day High : 1.81 Day Low : 1.69 Year High : 4.74 Year Low : 1.37 Volume : 20,400 |